Rockefeller Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
UCFA
GKWIM
YIA
Rockefeller Capital Management's PBE Position: Q2 2026 in Review
Rockefeller Capital Management increased its Invesco Biotechnology & Genome ETF (PBE) stake by 0.06% in Q2 2026, buying an estimated $494 and bringing the position to 10,673 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #1727.
Rockefeller Capital Management first reported a position in PBE in Q4 2020 and has held it in 23 quarters since. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.
- Rockefeller Capital Management held 10,673 shares of Invesco Biotechnology & Genome ETF worth $957K as of Q2 2026.
- Rockefeller Capital Management bought 6 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $494.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1727 holding.
- Rockefeller Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2020 and has held it in 23 quarters since.
- 105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.
Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.